Sign In
Buy QNCX
$0.97
+0.0406 (+4.38%)
At Close: Jun 23, 2026
Quince Therapeutics, Inc. (QNCX) Shareholder/Analyst Call Prepared Remarks Transcript
02:12pm, Thursday, 11'th Jun 2026
Quince Therapeutics, Inc. (QNCX) Shareholder/Analyst Call Prepared Remarks Transcript
Quince Therapeutics, Inc. (QNCX) M&A Call Prepared Remarks Transcript
06:00pm, Monday, 18'th May 2026
Quince Therapeutics, Inc. (QNCX) M&A Call Prepared Remarks Transcript
SOUTH SAN FRANCISCO, Calif., May 18, 2026 (GLOBE NEWSWIRE) -- Quince Therapeutics, Inc. (Nasdaq: QNCX) announced Phase 2a data evaluating LAM-001, an inhaled formulation of rapamycin (mTOR inhibitor),
SOUTH SAN FRANCISCO, Calif., May 18, 2026 (GLOBE NEWSWIRE) -- Quince Therapeutics, Inc. (Nasdaq: QNCX) announced Phase 2a data evaluating LAM-001, an inhaled formulation of rapamycin (mTOR inhibitor),
Quince Announces Acquisition of Orphai and up to $187 Million Private Placement to Advance Pulmonary Pipeline
09:26am, Monday, 18'th May 2026
SOUTH SAN FRANCISCO, Calif., May 18, 2026 (GLOBE NEWSWIRE) -- Quince Therapeutics, Inc. (Nasdaq: QNCX) announced it has acquired Orphai Therapeutics Inc., a clinical-stage biotechnology company. The a
Quince Therapeutics Settles Approximately $16.4 Million of Debt
08:30am, Monday, 30'th Mar 2026
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $QNCX #biotech--Quince Therapeutics, Inc. (Nasdaq: QNCX) today announced the successful settlement of the company's outstanding obligations under its l
Quince Therapeutics, Inc. (NASDAQ:QNCX) Given Average Recommendation of “Reduce” by Analysts
04:24am, Saturday, 28'th Mar 2026
Shares of Quince Therapeutics, Inc. (NASDAQ: QNCX - Get Free Report) have earned a consensus recommendation of "Reduce" from the seven analysts that are presently covering the company, Marketbeat.com
Quince Therapeutics, Inc. (NASDAQ:QNCX) Given Average Recommendation of “Reduce” by Analysts
04:16am, Tuesday, 03'rd Mar 2026
Shares of Quince Therapeutics, Inc. (NASDAQ: QNCX - Get Free Report) have received an average rating of "Reduce" from the nine brokerages that are currently covering the stock, MarketBeat Ratings repo
What Sparked Quince Therapeutics (QNCX) Stock To Rise 53% After Hours
01:51am, Friday, 13'th Feb 2026
Quince Therapeutics shares surged 53% after hours Thursday following the engagement of LifeSci Capital as financial advisor amid restructuring and strategic plans.
Quince Therapeutics Stock Plunges As Filing Shows Reverse Merger Plans, Bankruptcy Risks
12:27pm, Thursday, 12'th Feb 2026
Quince Therapeutics Inc (NASDAQ: QNCX) stock is trading sharply lower Thursday after the biotech company followed up Wednesday's rally with a Form 8-K that underscores how precarious its situation is.
Investors Purchase Large Volume of Quince Therapeutics Call Options (NASDAQ:QNCX)
04:34am, Thursday, 12'th Feb 2026
Quince Therapeutics, Inc. (NASDAQ: QNCX - Get Free Report) was the recipient of unusually large options trading on Wednesday. Stock investors acquired 28,800 call options on the company. This represen
Quince Therapeutics Stock Explodes 300% On Strategic Review
03:05pm, Tuesday, 10'th Feb 2026
Quince Therapeutics Inc shares are soaring Tuesday as the company has engaged LifeSci Capital to serve as its exclusive financial advisor.
Quince Therapeutics Engages LifeSci Capital as its Exclusive Financial Advisor to Explore Strategic Alternatives
04:05pm, Monday, 09'th Feb 2026
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $QNCX #biotech--Quince Therapeutics, Inc. (Nasdaq: QNCX), today announced that it has engaged LifeSci Capital to serve as its exclusive financial advis
Quince Therapeutics Announces Topline Results from Pivotal Phase 3 NEAT Clinical Trial of eDSP in Ataxia-Telangiectasia
03:10pm, Thursday, 29'th Jan 2026
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $QNCX #biotech--Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patient's own biolog
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $QNCX #biotech--Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patient's own biolog
